SCHEMBL3014317

SCHEMBL3014317

Cc1ccc(C(=O)Nc2ccnc(C(C)(C)C)c2)cc1Nc1ncnn1-c1cc(NC2CC2)ncn1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BRAF P15056 6/20 0.54
LCK P06239 6/20 0.49
KDR P35968 6/20 0.49
SRC P12931 6/20 0.49
INSR P06213 5/20 0.49
LYN P07948 5/20 0.49
HCK P08631 3/20 0.49
MAPK14 Q16539 6/20 0.42
MAPK13 O15264 2/20 0.42
MAPK12 P53778 2/20 0.42
MAPK11 Q15759 2/20 0.42
NPC1 O15118 1/20 0.39
LMNA P02545 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
RAF1 P04049 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017957 0.90 BRAF (0.47) BRAFLCKKDRSRCINSR
SCHEMBL3016856 0.86 BRAF (0.51) BRAFLCKKDRSRCINSR
SCHEMBL3021117 0.85 LCK (0.53) BRAFLCKKDRSRCINSR
SCHEMBL3020814 0.84 LCK (0.51) BRAFLCKKDRSRCINSR
SCHEMBL3024196 0.84 LCK (0.62) BRAFLCKKDRSRCINSR
SCHEMBL3017502 0.84 INSR (0.52) BRAFLCKKDRSRCINSR
SCHEMBL3016002 0.83 LMNA (0.48) BRAFLCKKDRSRCINSR
SCHEMBL3015581 0.82 INSR (0.59) BRAFLCKKDRSRCINSR
SCHEMBL3020918 0.82 MAPK14 (0.52) BRAFLCKKDRSRCINSR
SCHEMBL3018604 0.81 MAPK14 (0.58) BRAFLCKKDRSRCINSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100184765-A1 Protein Kinase Inhibitors and Methods for Using Thereof IRM LLC 2010-07-22 US claimed
EP-2170867-A1 PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF IRM LLC (BM) 2010-04-07 EP claimed
WO-2008157131-A1 PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF IRM LLC (BM) 2008-12-24 WO claimed
US-20100184765-A1 Protein Kinase Inhibitors and Methods for Using Thereof IRM LLC 2010-07-22 US disclosed
US-20100184765-A1 Protein Kinase Inhibitors and Methods for Using Thereof IRM LLC 2010-07-22 US disclosed
US-20100184765-A1 Protein Kinase Inhibitors and Methods for Using Thereof IRM LLC 2010-07-22 US disclosed
EP-2170867-A1 PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF IRM LLC (BM) 2010-04-07 EP disclosed
WO-2008157131-A1 PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF IRM LLC (BM) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184765-A1 Protein Kinase Inhibitors and Methods for Using Thereof BMX, FRK, FYN BRAF 33/4885LCK 8/4885KDR 182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.